I am betti_老虎社区_美港股上老虎

2021-12-07

I am betting on your mother

Ocugen Investors Are Betting On a Horse Than Can’t Win the Race

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":606614244,"tweetId":"606614244","gmtCreate":1638870615594,"gmtModify":1638870615594,"author":{"id":3577579226988656,"idStr":"3577579226988656","authorId":3577579226988656,"authorIdStr":"3577579226988656","name":"Baaboon","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>I am betting on&nbsp;your mother</body></html>","htmlText":"<html><head></head><body>I am betting on&nbsp;your mother</body></html>","text":"I am betting on your mother","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/606614244","repostId":1159607563,"repostType":2,"repost":{"id":"1159607563","kind":"news","pubTimestamp":1638861435,"share":"https://www.laohu8.com/m/news/1159607563?lang=&edition=full","pubTime":"2021-12-07 15:17","market":"us","language":"en","title":"Ocugen Investors Are Betting On a Horse Than Can’t Win the Race","url":"https://stock-news.laohu8.com/highlight/detail?id=1159607563","media":"InvestorPlace","summary":"Don't go bottom-fishing with OCGN stock even if it's at an enticing support level","content":"For technical traders, it might be tempting to accumulate shares of biopharmaceutical company&nbsp;Ocugen&nbsp;(NASDAQ:OCGN) because OCGN stock has come down to a seemingly fair price.\nYet, let’s not forget the old Warren Buffett saying. It goes something like this: price is what you pay, but value is what you actually get.\nSo, is OCGN a good value at its reduced price point? That depends, in large part, on Ocugen’s financials, which aren’t looking too healthy.\nMoreover, since Ocugen is a Covid-19 vaccine developer, we have to consider how the company is faring on the regulatory front. As it turns out, there are issues in that area, as well.\nA Closer Look at OCGN Stock\nBefore talking about support levels, we should discuss OCGN’s resistance level, which is definitely $15.\nIn February, May and November, the stock spiked to $15 before declining sharply.\nTherefore, if you’re bold enough to take a long position, you might consider taking profits at $15 just to stay safe.\nOn the other end of the spectrum, OCGN stock has strong support at $6.\nThe stock bounced off of that level in April and again in October, and stayed near $6 for five consecutive months starting in June.\nChecking in on Dec. 2, the share price is almost exactly $6. That might just be an eerie coincidence, but it feels meaningful.\nTherefore, from a price-action perspective, OCGN stock looks pretty tempting. Informed investors need to be big-picture thinkers, though, and check the company’s fundamentals as well.\nSo, let’s see how Ocugen’s faring on the fiscal front.\nFinancially Frail\nJust to give you a quick primer, Ocugen’s Covid-19 vaccine candidate is&nbsp;known as Covaxin.\nOcugen is&nbsp;co-developing&nbsp;Covaxin with India-based&nbsp;Bharat Biotech, and is advancing the drug in the U.S. and Canadian markets.\nIt’s worth noting that Ocugen also seeks to treat underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.\nLet’s be honest, though – Wall Street is much more interested in Covaxin’s progress (or lack thereof), which we’ll get to in a moment.\nRight now, the topic of discussion is Ocugen’s financials, and they’re not particularly encouraging.\nDuring&nbsp;2021’s third quarter, Ocugen generated zero total revenues.\nThe same could actually be said about the first three quarters of 2021.\nNow, let’s look at the bottom-line results. During 2021’s first three quarters, Ocugen sustained a net earnings loss of $43,784,000.\nThat’s significantly worse than the $30,578,000 net loss from the comparable period of 2020.\nSo far, this analysis isn’t painting Ocugen in a positive light. Will the outlook brighten when we focus on Covaxin’s progress with regulators?\nGood News, Bad News\nLet’s start with a development that should provide some relief to OCGN stock holders.\nThe Lancet, a widely respected medical journal,published the results&nbsp;of a Phase 3 trial of Covaxin.\nThe data indicates that Covaxin demonstrated a 93.4% efficacy rate against severe Covid-19.\nThat’s a great result, but there are other numbers to consider. Specifically, Covaxin demonstrated 77.8% overall efficacy against Covid-19, 63.6% efficacy against asymptomatic Covid-19 and 65.2% efficacy against the delta variant strain.\nThose lower figures might make Covaxin less useful in certain contexts.\nWorse yet, the U.S. Food and Drug Administration (FDA) recently issued aclinical holdon an Investigational New Drug application (IND) to evaluate Covaxin outside of the U.S.\nThat’s a stumbling block on the regulatory pathway, which Ocugen definitely didn’t need right now.\nThe Bottom Line\nIt’s a shame that Ocugen couldn’t keep up in the race to develop a Covid-19 vaccine that would gain traction.\nThe competition is fierce in this area, and unfortunately, Ocugen isn’t in a strong financial position to outdo or outlast its peers.\nTherefore, even if it’s trading at a strong support level, OCGN stock simply isn’t a buy right now.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Investors Are Betting On a Horse Than Can’t Win the Race</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Investors Are Betting On a Horse Than Can’t Win the Race\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 15:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/ocgn-stock-investors-are-betting-on-a-horse-than-cant-win-the-race/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nFor technical traders, it might be tempting to accumulate shares of biopharmaceutical company Ocugen (NASDAQ:OCGN) because OCGN stock has come down to a seemingly fair price.\nYet, let’s not forget the...\n\n<a href=\"https://investorplace.com/2021/12/ocgn-stock-investors-are-betting-on-a-horse-than-cant-win-the-race/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://investorplace.com/2021/12/ocgn-stock-investors-are-betting-on-a-horse-than-cant-win-the-race/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159607563","content_text":"For technical traders, it might be tempting to accumulate shares of biopharmaceutical company Ocugen (NASDAQ:OCGN) because OCGN stock has come down to a seemingly fair price.\nYet, let’s not forget the old Warren Buffett saying. It goes something like this: price is what you pay, but value is what you actually get.\nSo, is OCGN a good value at its reduced price point? That depends, in large part, on Ocugen’s financials, which aren’t looking too healthy.\nMoreover, since Ocugen is a Covid-19 vaccine developer, we have to consider how the company is faring on the regulatory front. As it turns out, there are issues in that area, as well.\nA Closer Look at OCGN Stock\nBefore talking about support levels, we should discuss OCGN’s resistance level, which is definitely $15.\nIn February, May and November, the stock spiked to $15 before declining sharply.\nTherefore, if you’re bold enough to take a long position, you might consider taking profits at $15 just to stay safe.\nOn the other end of the spectrum, OCGN stock has strong support at $6.\nThe stock bounced off of that level in April and again in October, and stayed near $6 for five consecutive months starting in June.\nChecking in on Dec. 2, the share price is almost exactly $6. That might just be an eerie coincidence, but it feels meaningful.\nTherefore, from a price-action perspective, OCGN stock looks pretty tempting. Informed investors need to be big-picture thinkers, though, and check the company’s fundamentals as well.\nSo, let’s see how Ocugen’s faring on the fiscal front.\nFinancially Frail\nJust to give you a quick primer, Ocugen’s Covid-19 vaccine candidate is known as Covaxin.\nOcugen is co-developing Covaxin with India-based Bharat Biotech, and is advancing the drug in the U.S. and Canadian markets.\nIt’s worth noting that Ocugen also seeks to treat underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.\nLet’s be honest, though – Wall Street is much more interested in Covaxin’s progress (or lack thereof), which we’ll get to in a moment.\nRight now, the topic of discussion is Ocugen’s financials, and they’re not particularly encouraging.\nDuring 2021’s third quarter, Ocugen generated zero total revenues.\nThe same could actually be said about the first three quarters of 2021.\nNow, let’s look at the bottom-line results. During 2021’s first three quarters, Ocugen sustained a net earnings loss of $43,784,000.\nThat’s significantly worse than the $30,578,000 net loss from the comparable period of 2020.\nSo far, this analysis isn’t painting Ocugen in a positive light. Will the outlook brighten when we focus on Covaxin’s progress with regulators?\nGood News, Bad News\nLet’s start with a development that should provide some relief to OCGN stock holders.\nThe Lancet, a widely respected medical journal,published the results of a Phase 3 trial of Covaxin.\nThe data indicates that Covaxin demonstrated a 93.4% efficacy rate against severe Covid-19.\nThat’s a great result, but there are other numbers to consider. Specifically, Covaxin demonstrated 77.8% overall efficacy against Covid-19, 63.6% efficacy against asymptomatic Covid-19 and 65.2% efficacy against the delta variant strain.\nThose lower figures might make Covaxin less useful in certain contexts.\nWorse yet, the U.S. Food and Drug Administration (FDA) recently issued aclinical holdon an Investigational New Drug application (IND) to evaluate Covaxin outside of the U.S.\nThat’s a stumbling block on the regulatory pathway, which Ocugen definitely didn’t need right now.\nThe Bottom Line\nIt’s a shame that Ocugen couldn’t keep up in the race to develop a Covid-19 vaccine that would gain traction.\nThe competition is fierce in this area, and unfortunately, Ocugen isn’t in a strong financial position to outdo or outlast its peers.\nTherefore, even if it’s trading at a strong support level, OCGN stock simply isn’t a buy right now.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1022,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":22,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/606614244"}